GERN has been the topic of several other reports. Needham & Company LLC raised shares of Geron from a hold rating to a buy rating and set a $3.00 price target on the stock in a report on Tuesday, April 9th. BidaskClub lowered shares of Geron from a hold rating to a sell rating in a report on Thursday, June 13th. Finally, B. Riley upped their price target on shares of Geron from $3.25 to $4.50 and gave the company a buy rating in a report on Friday, June 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $3.33.
Shares of NASDAQ GERN traded up $0.01 during mid-day trading on Thursday, hitting $1.16. The stock had a trading volume of 1,775,920 shares, compared to its average volume of 1,539,804. The stock’s 50 day moving average price is $1.35. Geron has a twelve month low of $0.95 and a twelve month high of $6.99. The stock has a market cap of $223.82 million, a price-to-earnings ratio of -7.25 and a beta of 2.60.
Large investors have recently bought and sold shares of the business. Amalgamated Bank purchased a new stake in Geron in the fourth quarter valued at $25,000. Rudd International Inc. purchased a new stake in Geron in the second quarter valued at $30,000. HRT Financial LLC boosted its holdings in Geron by 192.6% in the fourth quarter. HRT Financial LLC now owns 40,098 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 26,393 shares during the last quarter. BNP Paribas Arbitrage SA boosted its holdings in Geron by 6,429.2% in the first quarter. BNP Paribas Arbitrage SA now owns 36,629 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 36,068 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its holdings in Geron by 64.0% in the second quarter. DekaBank Deutsche Girozentrale now owns 41,000 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 16,000 shares during the last quarter. 31.39% of the stock is currently owned by institutional investors.
Geron Company Profile
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
Further Reading: NASDAQ
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.